Stay updated on Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.

Latest updates to the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedRelated topics now omit 'Prostate cancer' and 'MedlinePlus Genetics'. This removes disease context and linked educational resources from the page.SummaryDifference0.2%

- Check9 days agoChange DetectedMinor changes include addition of related topics such as Prostate cancer and MedlinePlus Genetics, and a revision label update to v3.3.4 (replacing v3.3.3). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedFooter now displays Revision: v3.3.3, replacing the previous Revision: v3.3.2 and removing the HHS Vulnerability Disclosure entry.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page now displays Revision: v3.3.2, and the Revision: v3.3.1 note has been removed. This appears to be a minor site version update with no impact on the study details, eligibility criteria, or user-facing content.SummaryDifference0.1%

- Check59 days agoChange DetectedA new revision label 'Revision: v3.3.1' has been added. Related topics including 'Prostate cancer', 'MedlinePlus Genetics', and 'Revision: v3.2.0' have been removed.SummaryDifference0.2%

- Check67 days agoChange DetectedAdded Prostate cancer and MedlinePlus Genetics as related topics. Removed the government funding status notice regarding NIH operations (the NIH Clinical Center).SummaryDifference0.6%

Stay in the know with updates to Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunogenic Nivolumab + Ipilimumab in Prostate Cancer Clinical Trial page.